VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2020 | CONQUER: galcanezumab in treatment-resistant migraine

Stewart Tepper • 24 May 2020
EAN 2020
Headache Antibodies Galcanezumab
Treatment Trial Updates

Stewart Tepper, MD, Professor of Neurology, Geisel School of Medicine at Dartmouth, Hanover, NH, discusses the results of the CONQUER study (NCT03559257), which evaluated the safety and efficacy of galcanezumab in patients with treatment-resistant episodic or chronic migraine. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Stewart Tepper

2:00
Discontinuation of anti-CGRP antibodies in non-responders
Stewart Tepper • 17 Jun 2022
19:11
Benefit of migraine prevention with erenumab
Stewart Tepper • 24 May 2020
2:05
AHS highlights: atogepant and zavegepant for migraine treatment
Stewart Tepper • 17 Jun 2022
7:37
Erenumab in migraine with or without aura: cardiovascular safety
Stewart Tepper • 24 May 2020

Related Videos

17:21
Nutritional approaches for migraine management
Mansoureh Togha et al. • 29 Sep 2023
2:55
Migraine prophylaxis: low budget solutions
Mansoureh Togha • 29 Sep 2023
3:32
Cinnarizine for the prophylaxis of migraine associated vertigo
Mansoureh Togha • 29 Sep 2023
7:31
Psychiatric comorbidities in patients with headache
Aynur Özge • 27 Sep 2023
The content of VJNeurology is intended for healthcare professionals